Clinical trial
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
NCT00006400 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00006400 |
|---|---|
| Title | Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia |
| Official title | Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hematologic Diseases, Anemia, Sickle Cell |
| Intervention type | Drug |
| Interventions | Hydroxyurea, Placebo |
| Enrollment | 193 |
| Start date | Aug 1, 2000 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Oct 13, 2000 |
| Last update posted | Aug 19, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: